|
|
||||||||
HORMONES AND SIGNALING
receptors and directly inhibits growth in human intestinal smooth muscle cells
Departments of Medicine and Physiology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, Virginia 23298
Submitted 9 January 2004 ; accepted in final form 26 May 2004
We have shown that human intestinal smooth muscle cells produce IGF-I and IGF binding protein-3 (IGFBP-3). Endogenous IGF-I acts in autocrine fashion to stimulate growth of these cells. IGFBP-3 inhibits the binding of IGF-I to its receptor and thereby inhibits IGF-I-stimulated growth. In several carcinoma cell lines and some normal cells, IGFBP-3 regulates growth independently of IGF-I. Two mechanisms for this effect have been identified: IGFBP-3 can directly activate transforming growth factor-
(TGF-
) receptors or it can undergo direct nuclear translocation. The aim of the present study was to determine whether IGFBP-3 acts independently of IGF-I and to characterize the mechanisms mediating this effect in human intestinal smooth muscle cells. The direct effects of IGFBP-3 were determined in the presence of an IGF-I receptor antagonist to eliminate its IGF-I-dependent effects. Affinity labeling of TGF-
receptors (TGF-
RI, TGF-
RII, and TGF-
RV) with 125I-labeled TGF-
1 showed that IGFBP-3 displaced binding to TGF-
RII and TGF-
RV in a concentration-dependent fashion. IGFBP-3 stimulated TGF-
RII-dependent serine phosphorylation (activation) of both TGF-
RI and of its primary substrate, Smad2(Ser465/467). IGFBP-3 also caused IGF-I-independent inhibition of basal [3H]thymidine incorporation. The effects of IGFBP-3 on Smad2 phosphorylation and on smooth muscle cell proliferation were independent of TGF-
1 and were abolished by transfection of Smad2 siRNA. Immunoneutralization of IGFBP-3 increased basal [3H]thymidine incorporation, implying that endogenous IGFBP-3 inhibits proliferation. We conclude that endogenous IGFBP-3 directly inhibits proliferation of human intestinal smooth muscle cells by activation of TGF-
RI and Smad2, an effect that is independent of its effect on IGF-I-stimulated growth.
insulin-like growth factor-I; Smad2; short interfering RNA
This article has been cited by other articles:
![]() |
P. M. Pereira-Fantini, S. L. Thomas, R. G. Taylor, E. Nagy, M. Sourial, P. J. Fuller, and J. E. Bines Colostrum Supplementation Restores Insulin-like Growth Factor -1 Levels and Alters Muscle Morphology Following Massive Small Bowel Resection JPEN J Parenter Enteral Nutr, May 1, 2008; 32(3): 266 - 275. [Abstract] [Full Text] [PDF] |
||||
![]() |
L O'Rear, L Longobardi, M Torello, B K Law, H L Moses, F Chiarelli, and A Spagnoli Signaling cross-talk between IGF-binding protein-3 and transforming growth factor-{beta} in mesenchymal chondroprogenitor cell growth J. Mol. Endocrinol., June 1, 2005; 34(3): 723 - 737. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Kuemmerle Endogenous IGF-I protects human intestinal smooth muscle cells from apoptosis by regulation of GSK-3{beta} activity Am J Physiol Gastrointest Liver Physiol, January 1, 2005; 288(1): G101 - G110. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |